Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...
The FDA has accepted uniQure’s applicatoin for its Huntington’s disease gene therapy under priority review, alongside a tentative plan to convene an advisory committee meeting. | The FDA has accepted ...
The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...
The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...
Audax sees the propensity for IL-12 drugs to bind receptors on peripheral immune cells as a driver of the dosing and toxicity ...
The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...
Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...
Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper ...
BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...
During a public hearing Wednesday to discuss a newly proposed rare disease framework, FDA center director Michael Davis, M.D.
Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results